SMARCB1 and cancer: Radko-Juettner et al. used data from 14 SMARCB1-mutant RT cell lines generated from a near-genome-wide CRISPR-Cas9 loss-of-function screen conducted by the Cancer Dependency Map Project (DepMap) and identified the E3 ligase DCAF5 as a specific vulnerability of RT cells with SMARCB1 loss-of-function.